hC Bioscience Appoints Heather Hirsch, Ph.D. as SVP of Translational Science and Cancer Biology, Strengthening Leadership Team in Advancing tRNA-Based Therapeutics

July 18, 2023 8:13 AM EDT | Source: Reportable, Inc.

Boston, Massachusetts--(Newsfile Corp. - July 18, 2023) - hC Bioscience, a pioneering biotech company dedicated to advancing tRNA-based therapeutics, has appointed Heather Hirsch, Ph.D., as the Senior Vice President of Translational Science and Cancer Biology. Hirsch, Ph.D. who will join a growing team of scientists, brings a wealth of experience and expertise, having served most recently as the Vice President of Clinical Translational Sciences at IMV Inc.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Heather Hirsch, Ph.D. has been appointed as the Senior Vice President of Translational Science and Cancer Biology at hC Bioscience, bringing extensive experience and expertise in cancer biology and translational sciences from her previous roles at Merck, Jounce Therapeutics, and, IMV Inc.
  • hC Bioscience is dedicated to advancing tRNA-based therapeutics to target protein dysfunction and revolutionize the treatment of genetically defined conditions, which account for 10-15% of all human diseases.
  • Hirsch Ph.D. appointment reinforces hC Bioscience's commitment to attracting top talent in the industry and driving advancements in precision medicine, positioning the company as a leader in the field.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/173915_figure1_550.jpg

Click image above to view full announcement.

About hC Bioscience
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience's innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

Contacts:

Savannah Beaver
3153683576
savannah@reportablenews.com

Source: hC Bioscience

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/173915

info